Physician profile
David King
NPI 1891788998
$796.38
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $197 · 2021: $158 · 2022: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $384.75 | 2019-2022 | |
| Smith+Nephew, INC. | $113.22 | 2019 | |
| Pacira Therapeutics, INC. | $51.24 | 2019-2020 | |
| Pylant Medical | $47.73 | 2022 | |
| Depuy Synthes Sales INC. | $45.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $33.82 | 2019 | |
| Zyla Life Sciences, INC. | $32.35 | 2019 | |
| Horizon Therapeutics Plc | $27.34 | 2022 | |
| Bioventus LLC | $15.95 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.68 | 2022 | |
| Stryker Corporation | $15.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.53 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.